β-Lactoglobulin Elevates Insulin and Glucagon Concentrations Compared with Whey Protein-A Randomized Double-Blinded Crossover Trial in Patients with Type Two Diabetes Mellitus

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

The researchers therefore hypothesized that BLG pre-meals would lower glucose levels compared with WPI in patients with T2DM.

Who Took Part

According to the abstract, 16 participants were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

The researchers therefore hypothesized that BLG pre-meals would lower glucose levels compared with WPI in patients with T2DM.

PubMed files the paper under topics including Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Glucagon, Insulin, Lactoglobulins and Postprandial Period.

Author keywords: CGM, beta-lactoglobulin, glycemic variability, pre-meal, type 2 diabetes mellitus and whey.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon in 16 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Nutrients), a journal based in Switzerland.

More context: the Glucagon compound page, all human trials.